Which patients are usually suited to injection first?

When a consultant mentions both an injectable collagen scaffold and possible knee replacement in the same conversation, the natural question is: how do I know which one actually applies to me?

The short answer lies in the pattern of damage — not just its severity. ChondroFiller™ injection is suited to patients with an isolated, focal patch of Grade III or IV cartilage loss in one compartment of the knee, where the surrounding cartilage borders remain largely intact. Think of it as a contained pothole on an otherwise serviceable road. Knee replacement, by contrast, addresses a fundamentally different picture: diffuse, multi-compartment joint-surface loss consistent with advanced Kellgren-Lawrence Grade IV osteoarthritis — widespread deterioration rather than a single focal lesion.

There is also an important middle group. Patients who have progressed to advanced KL Grade III or IV osteoarthritis but are not yet surgical candidates — whether because of age, fitness, or a preference to preserve the native joint — may also be considered for injectable scaffold treatment, where maintaining as much of the original joint as possible remains the clinical priority.

The decisional fork, then, is focal versus diffuse, and single-compartment versus multi-compartment collapse. A thorough assessment, including imaging and a specialist consultation, is needed to determine which category applies in any individual case.

What ChondroFiller injection is and how it works

ChondroFiller® liquid is a CE-marked Class III medical device — the same regulatory category as an implantable joint prosthesis — yet its physical form is quite different: a clear, injectable gel made from acid-extracted murine Type I collagen. Once placed inside the joint, the collagen undergoes an irreversible phase change at body temperature, shifting from a free-flowing liquid to a soft, stable gel that conforms to the contours of the cartilage defect space.

That gelling behaviour is central to how the treatment works. Rather than acting as a passive filler, the scaffold provides a three-dimensional matrix that attracts the patient's own progenitor cells — drawn from the synovial lining and the subchondral bone beneath the defect — into its structure. This process is known as acellular matrix-induced chondrogenesis: acellular because no donor cells are introduced (the product carries only the collagen matrix itself), and chondrogenesis because the recruited host cells are guided toward cartilage-forming activity. The scaffold promotes endogenous repair rather than supplying replacement tissue from outside the body.

Because the gel settles from the surface downward, it fills the defect space without disturbing the native cartilage bed or the bone beneath it. In current clinical practice, ChondroFiller is delivered as an ultrasound-guided outpatient injection, placed precisely into the focal lesion under image guidance. No incision, theatre admission, or general anaesthetic is required.

The structural difference from knee replacement surgery

The mechanical logic separating injection from replacement comes down to a single distinction: one approach adds material to a surviving surface; the other removes and replaces that surface entirely.

When ChondroFiller gel is placed into a focal cartilage defect under ultrasound guidance, it settles from above — occupying the space the missing cartilage once filled without disturbing the native cartilage bed or the bone beneath. The surrounding articular architecture remains intact. This is an additive intervention, and it depends on having a viable surface to work within.

Knee replacement operates on the opposite principle. When the joint surface has deteriorated beyond preservation — typically in diffuse, multi-compartment Kellgren-Lawrence Grade IV osteoarthritis — the damaged bone ends are removed and resurfaced with implants, reconstructing function from the bottom up. That subtractive step becomes appropriate precisely where injection is not: when there is no serviceable articular surface left to augment.

This additive-versus-subtractive distinction means the two approaches apply at different stages of structural degeneration, not simply different patient preferences about the same problem. They serve anatomically distinct joints.

Because injectable treatment and eventual surgery can appear on the same clinical horizon for some patients, the type of any intra-articular injection matters — not just whether to inject, but what is injected. For patients who may later require knee replacement, a large English cohort study of 38,494 primary TKAs found that prior steroid injection was associated with raised revision risk (HR 1.25), reoperation risk (HR 1.18), and surgical site infection risk (HR 3.10). A collagen scaffold does not carry the same immunosuppressive risk profile as corticosteroid, which is why the choice of injection agent, not just its timing, is worth raising with a specialist when planning a longer-term pathway.

Outcome data for ChondroFiller in focal knee defects

Published outcome data from four clinical studies of knee cartilage defects show ChondroFiller improving IKDC scores by approximately 30 points — a meaningful shift by any clinical measure. The International Knee Documentation Committee (IKDC) score runs from 0 to 100, with higher numbers indicating better knee function; the minimum clinically important difference (MCID) — the smallest improvement a patient would actually notice in daily life — is set at 16.7 points. Exceeding that threshold consistently across four independent investigations suggests a reliable functional signal rather than a study-specific finding.

The most detailed long-term data come from the Jerosch post-market clinical follow-up (PMCF) study, in which patients recorded a mean IKDC improvement of 32.4 points, reaching a final score of approximately 80 at three-year follow-up. It is worth being direct about the evidence base from the outset: these data originate from manufacturer-sponsored PMCF studies, and no head-to-head randomised trial comparing ChondroFiller injection with knee replacement or microfracture in a matched focal-defect population has been completed. That context shapes how the figures should be read — as a well-grounded basis for informed decision-making, not a comparison against the alternatives.

MRI data add a structural dimension to the functional picture. MOCART scores — which grade the quality and completeness of cartilage repair tissue visible on MRI — ranged from 81.6 to 84.3 in European studies, indicating more than 80% structural defect fill and good tissue integration. The progressive improvement from 65.3 at four weeks to 81.6 at twelve months reflects normal scaffold maturation as the repair tissue consolidates: a reassuring biological pattern rather than a delayed or incomplete result. Long-term survivorship beyond three years remains to be established, so these figures are best discussed with a specialist in the context of each individual joint.

When knee replacement becomes the more appropriate route

The border criterion is the practical dividing line. ChondroFiller's chondroinductive mechanism depends on the defect being genuinely focal — bounded by cartilage that remains structurally sound and can support inward cell migration. When that boundary dissolves into generalised surface loss, the 'focal defect' rationale no longer holds; there is no defined scaffold bed, and the surrounding tissue cannot contribute to repair in the way the product's mechanism requires.

The clearest signal that this threshold has been crossed is Kellgren-Lawrence Grade IV osteoarthritis spanning multiple compartments. At that point, knee replacement addresses something injection cannot: whole-compartment mechanical collapse that has altered the load-bearing geometry of the joint. Restoring alignment and distributing force across a new surface is a structural correction of a different order from filling a bounded defect.

No published figure specifies, in square centimetres, the precise defect area beyond which ChondroFiller injection is no longer appropriate. The criterion is described qualitatively in clinical literature — intact healthy borders and KL grading — and individual imaging and clinical assessment remain the practical determinants. That absence of a precise cut-off is itself informative: it underlines that the staging decision is reached through consultation, not from a scan measurement alone.

For patients whose imaging sits somewhere between clearly focal and clearly diffuse, the consultant will weigh defect geometry, OA grade, symptom burden, and patient goals together. Replacement is not a failure endpoint; it is the appropriate engineering solution for a structurally different problem.

Finding a specialist who can assess your options

Finding the right specialist means looking for someone whose practice genuinely spans both sides of this decision — familiar with injectable scaffold techniques for joint preservation and equally equipped to advise when surgical replacement is the more appropriate route. A clinician who works in one lane only cannot give a fully balanced staging opinion.

The questions worth raising at a first appointment are practical: Can the consultant interpret Kellgren-Lawrence grading and defect morphology together? Do they offer injectable scaffold pathways alongside referral into surgical assessment, or only one? The staging judgement described throughout this article — focal and bounded versus diffuse and multi-compartment — requires that dual perspective.

Search MSK lists specialists across the UK who offer ChondroFiller injection and joint-preservation assessment; filter by region and specialty to find one near you. Arriving with existing imaging — KL grade, defect boundaries, and any functional scores already recorded — will give the consultation a concrete and efficient starting point rather than one that begins from scratch.